

Erratum to: Idelalisib: First Global Approval

Anthony Markham

Published online: 7 October 2014
© Springer International Publishing Switzerland 2014

Erratum to: Drugs (2014) 74:1701–1707
DOI 10.1007/s40265-014-0285-6

Page 1701, abstract, lines 4–8: The following sentence, which previously read:

It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL).

Should read:

It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL).

Page 1701, section 1, paragraph 2, lines 5–9: The following sentence, which previously read:

The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL) who have received at least two other prior therapies [3, 4].

Should read:

The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL) who have received at least two other prior therapies [3, 4].

The online version of the original article can be found under doi:[10.1007/s40265-014-0285-6](https://doi.org/10.1007/s40265-014-0285-6).

A. Markham (✉)
Springer, Private Bag 65901, Mairangi Bay,
0754 Auckland, New Zealand
e-mail: dru@adis.com